VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$1.87 USD
+0.03 (1.47%)
Updated Sep 25, 2024 03:59 PM ET
After-Market: $1.87 0.00 (0.16%) 6:38 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VYNE 1.87 +0.03(1.47%)
Will VYNE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYNE
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Other News for VYNE
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
Buy Rating for VYNE Therapeutics Backed by Promising Early Phase Results and Strong Clinical Development Trajectory
VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202
VYNE Therapeutics to Participate in September Investor Conferences
VYNE Therapeutics GAAP EPS of -$0.22 beats by $0.01, revenue of $0.2M beats by $0.09M